Search Results

Intensity Therapeutics, Inc. announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024.

Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces first quarter 2024 financial results and provides a corporate update.

Portage Biotech Inc. reported that it has completed selling its equity holding in Intensity Therapeutics.

Intensity Therapeutics, Inc. announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland and selected countries in Europe.

Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.

Intensity Therapeutics, Inc. (Nasdaq: INTS) announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024.

Intensity Therapeutics, Inc. today announced that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the 2024 BIO CEO & Investor Conference on Monday, February 26, 2024, at the New York Marriott Marquis at 11:45am ET in the Uris Room.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system